After collecting FDA green lights for 90- and 180-day versions, the agency has cleared the latest generation of the Eversense ...
Ascendis Pharma has emerged as a potential threat to BioMarin’s Voxzogo, reporting phase 3 growth disorder data that exceeded ...
Five months after Rakovina Therapeutics pivoted toward artificial intelligence, the cancer-focused biotech has joined forces ...
A phase 3 trial of Daiichi Sankyo and Merck & Co.’s HER3-directed antibody-drug conjugate (ADC) has hit its primary endpoint, ...
With a trio of biotechs hitting the Nasdaq on Friday, it was easy to miss a smaller-scale public debut from another ...
An academic partnership to improve diversity in clinical trials has drafted its first industry team members. | An academic ...
PharmaLegacy Laboratories is snapping up BTS Research in hopes of expanding its reach as a preclinical CRO. | PharmaLegacy ...
Novo Nordisk isn’t done with the RNA deals, this time penning a $530 million biobucks deal to work with Korro Bio on two ...
Jazz Pharmaceuticals has posted fresh phase 2 data on zanidatamab that show the HER2-targeted bispecific antibody kept 59% of ...
As it works to diversify its methods for catching early cases of colorectal cancer, Exact Sciences has put forward clinical ...
Boehringer's phase 3 lung fibrosis trial hits primary endpoint, teeing up filings for Ofev successor
Boehringer Ingelheim has ended a decade of industrywide failures in idiopathic pulmonary fibrosis (IPF) by reporting a phase ...
Despite the analysts’ downbeat assessment, Oliver Sartor, M.D., Director of Radiopharmaceutical Trials and Professor of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback